Sheila DeWitt

This inventor holds 21 USPTO granted patents and 27 published patent applications and 5 EPO patents, primarily in Deuterium-Enhanced Compounds. Top assignees: Deuterx, LLC, Poxel Sa, Salarius Pharmaceuticals, Inc.. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sheila DeWitt. Retrieved from https://idiyas.com/inventor/sheila-dewitt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 27)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 1.3

ph-index = 7

Forward Citations = 199(Granted Patents)

Company Filing History:

Salarius Pharmaceuticals, Inc.

patents

Years Active: 2015-2024

Loading Chart...

Areas of Expertise:

Deuterium-Enriched

Thiazolidinedione

Piperidine

Isoindoline

Neurological Disorders

Metabolic Disorders

Crystalline Forms

Enantiopure Compounds

Oxidation

Compositions

Medical Treatments

Derivatives

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11918569 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2024-03-05),

2. 11820720 - 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2023-11-21),

3. 11773080 - Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same (2023-10-03),

4. 11535603 - Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same (2022-12-27),

5. 11491156 - 3-(substituted-4-oxoquinazolin-3(4)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2022-11-08),

6. 11319313 - Crystalline forms of deuterium-enriched pioglitazone (2022-05-03),

7. 11141411 - Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone (2021-10-12),

8. 11123336 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2021-09-21),

9. 11040925 - 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2021-06-22),

10. 10555946 - 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2020-02-11),

11. 10265305 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2019-04-23),

12. 10202316 - 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2019-02-12),

13. 10188639 - Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone (2019-01-29),

14. 9913845 - 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2018-03-13),

15. 9833445 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2017-12-05),

Title: Innovator Spotlight: Sheila DeWitt

Introduction: Sheila DeWitt is a prominent inventor based in Auburn, New Hampshire, who has made significant contributions to the field of medicinal chemistry. With a remarkable total of 21 patents, her work primarily focuses on developing novel compounds with therapeutic applications.

Latest Patents: Sheila's recent innovations include groundbreaking discoveries such as the 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same. This invention features 5-deuterium-enriched 2,4-thiazolidinediones and their derivatives, which are significant for treatment methods, including pharmaceutical formulations. Additionally, her patent on 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives also showcases her innovative prowess, providing deuterium-enriched compounds aimed at treating various diseases, including cancer and immune-related conditions.

Career Highlights: Throughout her career, Sheila has been associated with notable organizations, including Deuterx, LLC and Poxel Sa. These companies have provided her with an excellent platform to conduct her research and further her innovations in the pharmaceutical realm.

Collaborations: Sheila has worked alongside accomplished colleagues such as Vincent Jacques and Leonardus van der Ploeg. Their collaboration has likely contributed to her success in developing complex chemical structures and exploring therapeutic potentials.

Conclusion: Sheila DeWitt's extensive patent portfolio and her collaborations highlight her significant role in advancing medicinal chemistry. Her inventions pave the way for improved treatment options in various medical fields, showcasing the value of innovation in addressing healthcare challenges.

Profile summary based on public USPTO records.